Active substance
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| COPEGUS 200 MG FILM COATED TABLET | 200 mg | Film-coated tablet · Oral use | 168 Blister | SAR 0.00 | NCE · Prescription | ROCHE & CO LTD | Valid |
| RIBAVIN 200 MG CAPSULES | 200 mg | Capsule · Oral use | 60 Blister | SAR 590.05 | Generic · Prescription | THE ARAB PHARMACEUTICAL MANUFACTURING PSC (SAHAB) | Valid |
| RIAVIRIN | 200 mg | Capsule · Oral use | 60 Blister | SAR 590.05 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| RIAVIRIN | 200 mg | Capsule · Oral use | 30 Blister | SAR 330.40 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| VIRAZOLE 20MG-MLUPON RECONSTITUTON INHAL | 20 mg/ml | Solution · Oral use | 3 Vial | SAR 1841.30 | NCE · Prescription | I.C.N.PHARMACEUTICALS | Invalid · Not Marketed |
HEPATITIS C; RESPIRATORY SYNCYTIAL VIRUS
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| RIBAVIRIN | 200MG | capsule · oral | ZYDUS PHARMS USA | Prescription | 28 Oct 2005 |
| RIBAVIRIN | 200MG | tablet · oral | ZYDUS PHARMS USA | Prescription | 5 Dec 2005 |
| RIBAVIRIN | 200MG | tablet · oral | SANDOZ | Prescription | 3 Oct 2006 |
| RIBAVIRIN | 200MG | tablet · oral | AUROBINDO PHARMA | Prescription | 17 Sep 2009 |
| RIBAVIRIN | 200MG | capsule · oral | AUROBINDO PHARMA | Prescription | 17 Sep 2009 |
| VIRAZOLE | 6GM/VIAL | for solution · inhalation | BAUSCH | Discontinued | 31 Dec 1985 |
| REBETOL | 200MG **Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy**; 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | MERCK SHARP DOHME | Discontinued | 3 Jun 1998 |
| COPEGUS | 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | ROCHE | Discontinued | 3 Dec 2002 |
| REBETOL | 40MG/ML | solution · oral | SCHERING | Discontinued | 29 Jul 2003 |
| RIBAVIRIN | 200MG | capsule · oral | CHARTWELL RX | Discontinued | 6 Apr 2004 |
| RIBASPHERE | 200MG | capsule · oral | CHARTWELL RX | Discontinued | 6 Apr 2004 |
| RIBAVIRIN | 200MG | capsule · oral | TEVA | Discontinued | 4 Oct 2004 |
| RIBAVIRIN | 200MG | tablet · oral | HERITAGE PHARMA AVET | Discontinued | 5 Dec 2005 |
| RIBAVIRIN | 400MG; 600MG; 500MG | tablet · oral | ZYDUS PHARMS USA | Discontinued | 5 Dec 2005 |
| RIBAVIRIN | 200MG; 400MG; 600MG | tablet · oral | CHARTWELL RX | Discontinued | 5 Dec 2005 |
| RIBAVIRIN | 200MG; 400MG; 500MG; 600MG | tablet · oral | BEXIMCO PHARMS USA | Discontinued | 12 Aug 2014 |
| RIBAVIRIN | 6GM/VIAL | for solution · inhalation | CHARTWELL RX | Discontinued | 6 Oct 2016 |
Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults. Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation.
Cotronak is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b. Cotronak monotherapy must not be used.There is no safety or efficacy information on the use of Cotronak with other forms of interferon (i.e., not alfa-2b).Please refer also to the peginterferon alfa-2b or interferon alfa-2b Summary of Product Characteristics (SPC) for prescribing information particular to that product.
Ribavirin Teva is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, children 3 years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used. There is no safety or efficacy information on the use of Ribavirin with other forms of interferon (i.e. not alfa-2b). Naïve patients Adult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid HCV-RNA. Paediatric patients (children 3 years of age and older and adolescents) Ribavirin Teva is indicated, in a combination regimen with interferon alfa2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA. When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis. Previous treatment failure patients Adult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.
Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1). Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).
Ribavirin BioPartners is indicated for the treatment of chronic hepatitis-C-virus (HCV) infection in adults, children three years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used. There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b). Naïve patients Adult patients Ribavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid (HCV-RNA) (see section 4.4) Children three years of age and older and adolescents Ribavirin BioPartners is intended for use, in a combination regimen with interferon alfa-2b, for the treatment of children three years of age and older and adolescents, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA. When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis (see section 4.4). Previous-treatment-failure patients Adult patients Ribavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alfa monotherapy but who have subsequently relapsed (see section 5.1).
Ribavirin Mylan is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with interferon alfa-2b (adults, children (three years of age and older) and adolescents). Ribavirin monotherapy must not be used. There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b). Please refer also to the interferon alfa-2b summary of product characteristics (SmPC) for prescribing information particular to that product. Naïve patients Adult patients Ribavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for serum hepatitis-C-virus (HCV) RNA. Children and adolescents Ribavirin Mylan is indicated, in a combination regimen with interferon alfa-2b, for the treatment of children and adolescents three years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for serum HCV RNA. When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case-by-case basis (see section 4.4). Previously treatment-failure patients Adult patients Ribavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| VIRAZOLE | 02170140 | 6 G / VIAL | POWDER FOR SOLUTION; AEROSOL · INHALATION | BAUSCH HEALTH, CANADA INC. |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | RIBAVIRIN 200 MG TABLET | $0.45069 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.